e8vk
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 20, 2006
Date of Report (Date of earliest event reported)
VALEANT
PHARMACEUTICALS INTERNATIONAL
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1-11397
|
|
33-0628076 |
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
3300 Hyland Avenue
Costa Mesa, California
92626
(Address of principal executive offices)
( Zip Code)
(714) 545-0100
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
|
|
|
Item 4.02 |
|
Non-Reliance on Previously Issued Financial Statements or a Related
Audit Report or Completed Interim Review. |
(a) As previously announced, Valeant Pharmaceuticals International (the Company) received a
request from the Securities and Exchange Commission (the SEC) for data on its stock option
granting practices since January 1, 2000 as part of an informal inquiry. The Company initiated a
review of its option grants and continues to cooperate with the SEC inquiry. This review, which
covers option grants by the Company since its initial public offering in 1982, is being conducted
under the direction of a special committee of independent directors of the Board of Directors with
the assistance of outside legal counsel. The special committee has not completed its work on the
review nor reached final conclusions.
On October 20, 2006, after receiving from the special committee a report on certain
preliminary results of its review, the Board of Directors concluded that as a result of errors in
the Companys accounting for stock options, financial statements for certain prior periods will
need to be restated. The special committee reported that it has determined, with respect to
broad-based grants in 1997 and subsequent years, the Company should have used different measurement
dates for the purpose of computing compensation expense for those stock option grants in accordance
with Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees. While
the special committee has not yet reached a definitive conclusion as to the causes of these errors,
new accounting measurement dates are being applied to the affected option grants, and the Company
expects to recognize material additional non-cash, stock-based compensation expense for the
affected periods. Because the special committee has not completed its review, the Company has not
yet determined the magnitude of the restatement or what periods beyond those specified above will
ultimately be affected, but based upon the review of these grants, the Board of Directors, upon
recommendation of the Finance and Audit Committee, determined that the Companys annual and interim
financial statements,
earnings press releases and similar communications previously issued by the Company for and after
1997 should no longer be relied upon.
The Company intends to file its restated financial statements as soon as practicable after the
completion of the special committees review and an audit of such restated financial statements. Any additional non-cash, stock-based compensation expense recorded for the
periods in question will have the effect of decreasing income from operations, net income, and net
income per share (basic and diluted) in periods in which the Company reported a profit and
increasing loss from operations, net loss, and net loss per share in periods in which the Company
reported a loss. There may be other impacts on the financial statements of the Company and there
may be income tax consequences to the Company arising from the restatement, including the reversal
of certain tax benefits. The Company believes that the additional non-cash stock-based
compensation expense and any income tax consequences will not affect the Companys current cash
position or previously reported revenues.
Because the special committees review
and additional reviews by management have not been completed, it is possible that additional issues may be identified.
The chairman of the Finance and Audit Committee has discussed the matters described in this
Item 4.02(a) with PricewaterhouseCoopers LLP, the Companys independent registered public
accounting firm.
Item 7.01 Regulation FD Disclosure.
The Company notes that the majority of errors in accounting for options identified to date by
the special committee pertains to options granted prior to the change in the Companys Board of
Directors and management in June 2002. Additional errors were found in accounting for certain
options granted to employees since the board and management change, but none of the errors related
to options granted to the current Chief Executive Officer or Chief Financial Officer.
Item 8.01 Other Events.
Until the special committee has completed its review of the Companys option grant practices
and an audit of restated periods is completed, the Company will be unable to file with the Securities and Exchange Commission
regular periodic reports relating to its operating results and financial condition. At this time,
the Company expects that it will not file its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2006 by the due date. The Company cannot predict when it will complete the
restatement of its previously issued financial statements or be able to file its Form 10-Q for the
quarter ended September 30, 2006. The failure of the Company to remain current in its periodic
reporting obligations could have material adverse consequences for the Company. These adverse
consequences could include compliance issues under the information reporting requirements of the
Companys outstanding convertible and high-yield notes, which if not timely cured could result in
the acceleration of the outstanding amounts due under those notes.
Forward-Looking Statements
This Current Report contains forward-looking statements, including, but not limited to,
statements regarding preliminary results of the Companys review of options practices and related
charges, expenses and other items based on the Companys current expectations and involve risks and
uncertainties, including, but not limited to, risks and uncertainties relating to identification of
additional accounting errors or corrections, and/or additional recommendations of the special
committee, and other risks detailed from time to time in the Companys SEC filings, including its
Annual Report on Form 10-K for the year ended December 31, 2005. The Company cautions the reader
that these factors, as well as other factors described in its SEC filings, are among the factors
that could cause actual results to differ materially from the expectations described in the
forward-looking statements. The Company also cautions the reader that undue reliance should not be
placed on any of the forward-looking statements, which speak only as of the date of this Current
Report. The Company undertakes no responsibility to update any of these forward-looking statements
to reflect events or circumstances after the date of this Current Report or to reflect actual
outcomes.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
VALEANT PHARMACEUTICALS INTERNATIONAL
|
|
Date: October 23, 2006 |
/s/ Bary G. Bailey
|
|
|
Name: |
Bary G. Bailey |
|
|
Title: |
Executive Vice President, Chief
Financial Officer |
|
|